James Mock, MD
Cardiovascular Disease · Las Vegas, NVNPI 1417046822
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Pharmacosmos Therapeutics Inc. accounts for 62.5% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $8,701 and has fallen 87.7% since, to $1,073 in 2025.
Across 103 payments — averaging $123.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$8K
- Bard Peripheral Vascular, Inc.$1K
- Amgen$444
- Abbott$417
- E.r. Squibb & Sons, L.L.C.$345
- Novartis$306
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$7,20057%
- Travel & lodging$1,37211%
- Food & beverage$3,70129%
- Education$4133%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 7 | $7,929 |
| Bard Peripheral Vascular, Inc. | 8 | $1,419 |
| Amgen | 5 | $444 |
| Abbott | 5 | $417 |
| E.r. Squibb & Sons, L.L.C. | 7 | $345 |
| Novartis | 15 | $306 |
| Pfizer | 3 | $265 |
| Merck | 12 | $242 |
| Alnylam Pharmaceuticals Inc. | 6 | $208 |
| Bridgebio Pharma, Inc. | 3 | $191 |
| Philips North America LLC | 3 | $168 |
| Sanofi-aventis U.S. LLC | 6 | $114 |
| Abiomed | 2 | $101 |
| Johnson & Johnson | 6 | $89 |
| AstraZeneca | 5 | $88 |
| Impulse Dynamics (USA) Inc. | 1 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $69 |
| Cleerly, Inc. | 1 | $50 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
| Boston Scientific | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Edwards Lifesciences | 1 | $26 |
| Boehringer Ingelheim | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$7,856
- Venclose Maven Catheter$1,106
- Repatha$369
- VYNDAQEL$247
- CAMZYOS$240
- Accent Pacemaker$149
- Attruby$143
- AMVUTTRA$140
- (0792) MM IVUS Other$128
- VENOVO$126
- Confirm Rx$102
- ENTRESTO$101
How this compares
$12,685 in reported general payments places this provider in the 75th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 172 | $223,808 |
| XareltoRivaroxaban | 96 | $99,090 |
| EntrestoSacubitril/Valsartan | 22 | $31,591 |
| FarxigaDapagliflozin Propanediol | 11 | $13,966 |
| Repatha SureclickEvolocumab | 11 | $11,489 |
| Praluent PenAlirocumab | 21 | $11,340 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 22 | $4,930 |
| Nebivolol Hcl | 65 | $4,560 |
| Metoprolol Succinate | 156 | $2,646 |
| Bisoprolol Fumarate | 35 | $2,568 |
| Rosuvastatin Calcium | 115 | $1,851 |
| Losartan Potassium | 143 | $1,465 |
| Dofetilide | 12 | $1,322 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 67 | $1,318 |
| Ezetimibe | 62 | $1,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $265 | $223,808172 claims |
| Johnson & JohnsonXarelto | $89 | $99,09096 claims |
| NovartisEntresto | $306 | $31,59122 claims |
| AstraZenecaFarxiga | $88 | $13,96611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.